Results 11 to 20 of about 2,605,313 (261)

Primary cytoreductive surgery or interval cytoreductive surgery

Taiwanese Journal of Obstetrics & Gynecology
Yiu-Tai Li, Szu-Ting Yang, Peng-Hui Wang
doaj   +4 more sources

Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study

World Journal of Surgical Oncology, 2022
Background Cytoreductive surgery followed by systemic chemotherapy is the standard of treatment in advanced ovarian cancer where feasible. Neoadjuvant chemotherapy (NACT) followed by surgery is applicable where upfront cytoreductive surgery is not ...
Ester Miralpeix, Josep-Maria Sole-Sedeno, Cristina Rodriguez-Cosmen, Alvaro Taus, Maria-Dolors Muns, Berta Fabregó, Gemma Mancebo   +6 more
doaj   +2 more sources

The efficacy of cytoreductive surgery for oligometastatic prostate cancer: a meta-analysis

World Journal of Surgical Oncology, 2021
Backgrounds At present, the application of tumor reduction surgery in oligometastatic prostate cancer has aroused extensive discussion among urologists, but clinicians have not reached a consensus on this issue.
Bisheng Cheng, Shuchao Ye, Peiming Bai
doaj   +2 more sources

The current role of secondary cytoreductive surgery for recurrent ovarian cancer

Frontiers in Oncology, 2022
Ovarian cancer represents worldwide the second most frequent and the most fatal gynecological malignancy, with approximately two thirds of the patients presenting with advanced disease. Cytoreductive surgery, primary or after neoadjuvant chemotherapy, in
Eelco de Bree, Dimosthenis Michelakis, Elisavet Anagnostopoulou   +2 more
doaj   +2 more sources

Impact of postoperative infection on changes in leucocyte levels in early postoperative period in patients undergoing splenectomy during cytoreductive surgery for gynaecological malignancy [PDF]

BMC Cancer
Background In cytoreductive surgery for gynecological cancers, 13-25% of patients require splenectomy. Therefore, hematological parameters change in the post-splenectomy period, especially leucocytosis and thrombocytosis.
Yeşim Özkaya Uçar, Tufan Arslanca, Okan Aytekin, Gülşah Tiryaki Güner, Serpil Ünlü, Günsu Kimyon Cömert, Fatih Kılıç, Aziz Ahmet Sürel, Taner Turan   +8 more
doaj   +2 more sources

Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial

Journal of Clinical Oncology, 2023
PURPOSE In patients with peritoneal metastasis (PM) from gastric cancer (GC), chemotherapy is the treatment of choice. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are still being debated. This randomized, controlled,
B. Rau, Hauke Lang, Alfred Koenigsrainer, Ines Gockel, H. Rau, Hendrik Seeliger, Christian Lerchenmueller, D. Reim, Roger Wahba, Martin Angele, S. Heeg, Tobias Keck, Arved Weimann, Stefan Topp, P. Piso, A. Brandl, Silke Schuele, Peter Jo, J. Pratschke, Sandra Wegel, A. Rehders, N. Moosmann, J. Gaedcke, Volker Heinemann, E. Trips, Markus Loeffler, P. Schlag, P. Thuss-Patience   +27 more
semanticscholar   +1 more source

Comparison of Cytoreductive Surgery and Resection of Isolated Peritoneal Metastases in Patients with Peritoneal Metastases from Colorectal Cancer: A Retrospective Study

Journal of the Anus, Rectum and Colon, 2023
Objectives: This study aimed to compare the short and long-term outcomes of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy and resection of isolated peritoneal metastases in patients with peritoneal metastases from colorectal cancer
Shinya Yoshida, Yasuyuki Kamada, Koya Hida, Kazuyuki Okada, Kazutaka Obama, Satoshi Morita, Toshiyuki Kitai, Yutaka Yonemura   +7 more
doaj   +1 more source

Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer

JAMA Surgery, 2022
Key Points Question Does hyperthermic intraperitoneal chemotherapy (HIPEC) after primary or interval cytoreductive surgery increase survival in patients with ovarian cancer?
M. Lim, Suk-Joon Chang, Boram Park, H. Yoo, C. Yoo, B. Nam, Sang-Yoon Park   +6 more
semanticscholar   +1 more source

Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study [PDF]

Obstetrics & Gynecology Science, 2020
ObjectiveThe primary objective was to assess the feasibility of robotic-assisted interval cytoreductive surgery for achieving complete cytoreduction for patients with advanced-stage ovarian cancer. The secondary objective was to examine the perioperative
Semiramis L. Carbajal-Mamani, David Schweer, Merry J. Markham, Ashwini K. Esnakula, Joseph R. Grajo, Jacqueline C. Castagno, Joel Cardenas-Goicoechea   +6 more
doaj   +1 more source

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.

New England Journal of Medicine, 2021
BACKGROUND Treatment for patients with recurrent ovarian cancer has been mainly based on systemic therapy. The role of secondary cytoreductive surgery is unclear.
P. Harter, J. Sehouli, I. Vergote, G. Ferron, A. Reuss, W. Meier, S. Greggi, Berit J. Mosgard, F. Selle, F. Guyon, C. Pomel, F. Lécuru, R. Zang, E. Åvall-Lundqvist, Jae-weon Kim, J. Ponce, F. Raspagliesi, G. Kristensen, J. Classe, P. Hillemanns, P. Jensen, A. Hasenburg, S. Ghaem-Maghami, M. Mirza, B. Lund, A. Reinthaller, A. Santaballa, A. Olaitan, F. Hilpert, A. du Bois   +29 more
semanticscholar   +1 more source